IN2014MN02228A - - Google Patents

Info

Publication number
IN2014MN02228A
IN2014MN02228A IN2228MUN2014A IN2014MN02228A IN 2014MN02228 A IN2014MN02228 A IN 2014MN02228A IN 2228MUN2014 A IN2228MUN2014 A IN 2228MUN2014A IN 2014MN02228 A IN2014MN02228 A IN 2014MN02228A
Authority
IN
India
Prior art keywords
jak2
inden
imidazo
pyrazol
pyridin
Prior art date
Application number
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2014MN02228A publication Critical patent/IN2014MN02228A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2228MUN2014 2012-06-14 2013-06-05 IN2014MN02228A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659679P 2012-06-14 2012-06-14
PCT/US2013/044211 WO2013188184A1 (en) 2012-06-14 2013-06-05 Inhibitor of jak1 and jak2

Publications (1)

Publication Number Publication Date
IN2014MN02228A true IN2014MN02228A (enExample) 2015-07-17

Family

ID=48626679

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2228MUN2014 IN2014MN02228A (enExample) 2012-06-14 2013-06-05

Country Status (14)

Country Link
US (1) US9062050B2 (enExample)
EP (1) EP2861231B1 (enExample)
JP (1) JP6092376B2 (enExample)
KR (1) KR20150008907A (enExample)
CN (1) CN104349775B (enExample)
AU (1) AU2013274641B2 (enExample)
BR (1) BR112014030651A2 (enExample)
CA (1) CA2871659C (enExample)
EA (1) EA201492104A1 (enExample)
ES (1) ES2605827T3 (enExample)
IN (1) IN2014MN02228A (enExample)
MX (1) MX2014015271A (enExample)
WO (1) WO2013188184A1 (enExample)
ZA (1) ZA201407940B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115141195B (zh) * 2021-03-03 2024-02-06 成都先导药物开发股份有限公司 一种nuak抑制剂及其用途
WO2023086320A1 (en) * 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
AU2013274641A1 (en) 2014-11-20
US9062050B2 (en) 2015-06-23
KR20150008907A (ko) 2015-01-23
CA2871659C (en) 2017-04-04
MX2014015271A (es) 2015-03-05
BR112014030651A2 (pt) 2017-06-27
CA2871659A1 (en) 2013-12-19
EA201492104A1 (ru) 2015-06-30
CN104349775A (zh) 2015-02-11
AU2013274641B2 (en) 2015-09-24
EP2861231A1 (en) 2015-04-22
WO2013188184A1 (en) 2013-12-19
ES2605827T3 (es) 2017-03-16
EP2861231B1 (en) 2016-08-31
JP2015519396A (ja) 2015-07-09
ZA201407940B (en) 2016-05-25
JP6092376B2 (ja) 2017-03-08
US20150133490A1 (en) 2015-05-14
CN104349775B (zh) 2017-06-06

Similar Documents

Publication Publication Date Title
IN2014MN02228A (enExample)
IL290905A (en) Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
PH12014501986A1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
LT3418281T (lt) Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
IL280513A (en) Imidazo[2,1-B]pyridazines as TRK inhibitors
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
PT3621966T (pt) Derivados de pirazole[1,5-a]pirimidina como inibidores de cinase jak
LV14663A (lv) Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm
UA84238U (en) 3-(31,51-ditertbutyl-41-hydroxyphenyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole hydrochloride exhibiting antitumor properties